



21 February 2020
EMA/CVMP/70564/2020
Veterinary Medicines Division

MRL summary opinion¹

Bupivacaine

Porcine

On 20 February 2020, the Committee for Medicinal Products for Veterinary Use adopted an opinion² recommending the inclusion of bupivacaine in porcine in Table 1 (Allowed substances) of the Annex to Commission Regulation (EU) No 37/2010 of 22 December 2009, in accordance with the following table:

Pharmacologically active substance	Marker residue	Animal species	MRLs	Target tissues	Other provisions	Therapeutic classification
Bupivacaine	NOT APPLICABLE	Porcine	No MRL required	NOT APPLICABLE	For use in piglets up to 7 days of age For cutaneous and epilepsional use only	Local anaesthetic

¹ Summaries of opinion are published without prejudice to the Commission Decision.

² Applicants may request re-examination of any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to request such re-examination within 15 days of receipt of the opinion

